Abstract
New technological advances allow personalized medicine to be possible for staging, therapeutic planning, and monitoring the therapeutic response of cancer patients. Molecular imaging such as positron emission tomography (PET) has been widely used in clinical oncology. Currently, 18F-labeled fluorodeoxyglucose (18F-FDG) PET is used in more than 90 % of all molecular imaging procedures. Success of the 18F-FDG-PET is also recognized with certain drawbacks. Special attention has been devoted to the development of new tracers and technologies for better evaluation of tumor burden. Accurate and reliable imaging studies are needed to identify cancer at early stage, to proper stage for treatment plans, and to provide biomarkers for optimal assessment of therapeutic response. Targeted therapies for metastatic renal cell carcinoma (mRCC) have become the standard of practice. Molecular imaging is likely to play a greater role in the selection of patients with mRCC for treatment and for monitoring response. In this chapter, we outline the clinical utility of FDG-PET (PET/CT) for RCC and brief discussion of new radiotracers under investigation.
| Original language | English |
|---|---|
| Title of host publication | Renal Cancer |
| Subtitle of host publication | Contemporary Management |
| Publisher | Springer New York |
| Pages | 93-111 |
| Number of pages | 19 |
| ISBN (Electronic) | 9781461472360 |
| ISBN (Print) | 9781461472353 |
| DOIs | |
| State | Published - Jan 1 2013 |
